ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com
1. 5ÔÂ11ÈÕ£¬ÉϺ£Á§µÀÒ½Ò©¿Æ¼¼ÓÐÏÞ¹«Ë¾Ðû²¼£¬¹«Ë¾×ÔÖ÷¿ª·¢µÄÖÎÁÆÑ×Ö¢ÐÔ³¦²¡First-in-classÐÂÒ©LD09163Ƭ£¬INDÉêÇë»ñµÃÃÀ¹úFDAÅú×¼£¬Õýʽ½øÈëÁÙ´²¿ª·¢½×¶Î¡£
2. 5ÔÂ13ÈÕ£¬°Ù¼ÃÉñÖÝÔó²¼ÌæÄὺÄÒÐÂ˳Ӧ֢»ñÅú£¬ÁªºÏ°ÂÍ×Öéµ¥¿¹ÊÊÓÃÓÚ¼ÈÍù½ÓÊܹýÖÁÉÙ¶þÏßϵͳÐÔÖÎÁƵĸ´·¢»òÄÑÖÎÐÔÂËÅÝÐÔÁܰÍÁö£¨R/R FL£©»¼Õß¡£Ôó²¼ÌæÄᣨÉÌÆ·Ãû£º°ÙÔÃÔó£©ÊÇÒ»¿î²¼Â³¶ÙÊÏÀÒ°±ËἤøÒÖÖÆ¼Á£¨BTKi£©¡£
3. 5ÔÂ14ÈÕ£¬CDEÍøÕ¾ÏÔʾ£¬°¢Ë¹Àû¿µµÄ±¾ÈðÀûÖéµ¥¿¹£¨benralizumab£©×¢ÉäÒºÐÂ˳Ӧ֢ÉÏÊÐÉêÇë»ñµÃÊÜÀí£¬ÍÆ²â˳Ӧ֢Ϊ6-11ËêÊÈËáÐÔÁ£Ï¸°ûÐÔÏø´»¼ÕߵĸԶ×㬳ÖÖÎÁÆ¡£
4. 5ÔÂ13ÈÕ£¬ÉϺ£Ò½Ò©Ðû²¼Í¨¸æ¿ËÈÕ×ÔÖ÷Ñз¢µÄI031Ƭ»ñÅúÁÙ´²¡£I031ÊÇÒ»¿îС·Ö×ÓÒÖÖÆ¼Á£¬ÄܶÔÖ×ÁöÔöÖ³±¬·¢ÒÖÖÆ×÷Óá£ÁÙ´²Ç°Ñо¿ÏÔʾI031ÄÜÔÚÈËÔ´Ö×Áö¶¯ÎïÄ£×ÓÉÏÆðµ½ÒÖÖÆÖ×ÁöÉú³¤µÄ×÷Óá£
1. 5ÔÂ14ÈÕ£¬ÎäÌTakeda£©ºÍAC ImmuneÐû²¼¾ÍºóÕߵİÐÏòÓж¾ÐÎʽµí·ÛÑùÂѰצ£¨A¦Â£©µÄÃâÒßÁÆ·¨£¬°üÀ¨ÓÃÓÚÖÎÁư¢¶û´Äº£Ä¬²¡£¨AD£©µÄACI-24.060£¬Ç©ÊðÁËÒ»Ïî×ܶîÁè¼Ý21ÒÚÃÀÔªµÄÈ«Çò¶À¼ÒÑ¡ÔñºÍÔÊÐíÐÒé¡£
1. ¿ËÈÕ£¬Ò®Â³´óѧµÄStefan SomloÍŶÓÓÚÔÚNature CommunicationsÉϽÒÏþÌâΪ¡°Glis2 is an early effector of polycystin signaling and a target for therapy in polycystic kidney disease¡±µÄÎÄÕ£¬Ñо¿Åú×¢Glis2ʧ»î¿ÉÒÖÖÆ¶àÄÒÉö²¡Ï£Íû£¬ÌáÐÑGlis2ÊÇCDCAµÄ¹¦Ð§°Ðµã£¬Ò²ÊÇÖÎÁÆADPKDµÄDZÔڰе㡣
[1] Zhang, C., Rehman, M., Tian, X. et al. Glis2 is an early effector of polycystin signaling and a target for therapy in polycystic kidney disease. Nat Commun 15, 3698 (2024). https://doi.org/10.1038/s41467-024-48025-6